Live Webinar

Building a Cellular Therapy Program in the Community Oncology Setting: Perspectives and Lessons Learned

Presented by The Community Oncology Alliance

-- Days : -- HRS : -- MIN : -- SEC
Register Now →
Logo Image

October 2026

Robert Z. Orlowski, MD, PhD | Image: MD Anderson Cancer Center

Panel Confronts the Practical Barriers to Bringing Bispecifics Into Community Myeloma Care

ByMary Caffrey

At a Stakeholder Interchange convened by The American Journal of Managed Care® in Houston, Texas, oncologists and pharmacists from academic and community practices debated how teclistamab- and talquetamab-based regimens stack up against CAR T-cell therapy in second-line multiple myeloma, and what it will take—staffing, caregiver support, hospital partnerships, and payer buy-in—to move step-up dosing out of the hospital and into the clinic.

EBO horizontal thumb | Image: AJMC

A Patient-Centered Reconstruction of 340B in Oncology: Transparency, Equity, and Site-of-Care Accountability

ByLucio N. Gordan, MD,R. Steven Paulson, MD,David T. Wenk, MD,Paul A. S. Fishkin, MD,David R. Drosick, MD,Tracy W. Dobbs, MD,Richard M. Ingram, MD, FASCO,Rupesh J. Parikh, MD,Michael A. Danso, MD,Brian J. Heller, MD,Manojkumar Bupathi, MD, MS,David Cosgrove, MD,Mark T. Fleming, MD

Community oncology leaders urge 340B overhaul so drug discounts follow vulnerable cancer patients, with audits, transparency, and tighter contract-pharmacy rules. This commentary will be featured on the Cover of the October issue of Evidence-Based Oncology.